Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Part of paid clinical trials in San Diego, California.

Sponsor
University of California, San Diego
Study ID
NCT04501939
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cirmtuzumab — DRUG
    Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg
  • Venetoclax — DRUG
    Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.

Study Details

Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab consolidation in patients with measurable disease on venetoclax.

Key Dates

Start date
Aug 6, 2020
Status verified
Aug 2025
Primary completion
Jul 22, 2026
Completion
Jul 22, 2026

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cirmtuzumab + Venetoclax
    All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.

Primary Outcome Measure

Cancer response to treatment [ Time Frame: 6-24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSD Koman Family Outpatient PavilionSan DiegoCalifornia92037-

Find similar trials in San Diego, CA

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
UCSD Koman Family Outpatient Pavilion· San Diego, CA

Related Studies